For research use only. Not for therapeutic Use.
Inaxaplin (VX-147) is an orally active apolipoprotein L1 (APOL1) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease[1].
Inaxaplin is an apolipoprotein L1 function inhibitor[1].
| Catalog Number | I029298 |
| CAS Number | 2446816-88-0 |
| Synonyms | 3-[5,7-difluoro-2-(4-fluorophenyl)-1H-indol-3-yl]-N-[(3S,4R)-4-hydroxy-2-oxopyrrolidin-3-yl]propanamide |
| Molecular Formula | C21H18F3N3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H18F3N3O3/c22-11-3-1-10(2-4-11)18-13(14-7-12(23)8-15(24)19(14)27-18)5-6-17(29)26-20-16(28)9-25-21(20)30/h1-4,7-8,16,20,27-28H,5-6,9H2,(H,25,30)(H,26,29)/t16-,20+/m1/s1 |
| InChIKey | CTXLPYZCBOVVQK-UZLBHIALSA-N |
| SMILES | C1C(C(C(=O)N1)NC(=O)CCC2=C(NC3=C2C=C(C=C3F)F)C4=CC=C(C=C4)F)O |
| Reference | [1]. WO2020131807 |
